Cue Biopharma reports Q3 2026 results, CUE-221 CSU data and CUE-401 dosing start
The company disclosed Phase 2 chronic spontaneous urticaria data for CUE-221 and the start of first-in-human dosing for CUE-401, alongside quarterly financials.
SEC filing